Squarepoint
MDGL icon

Squarepoint’s Madrigal Pharmaceuticals MDGL Stock Holding History

Squarepoint’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.36M Sell
4,500
-1,300
-22% -$621K ﹤0.01% 2060
2025
Q4 		$3.38M Sell
5,800
-10,200
-64% -$5.21M ﹤0.01% 1711
2025
Q3 		$7.34M Buy
16,000
+5,100
+47% +$1.9M 0.01% 1239
2025
Q2 		$3.3M Buy
10,900
+2,500
+30% +$745K ﹤0.01% 1736
2025
Q1 		$2.78M Sell
8,400
-8,600
-51% -$2.83M ﹤0.01% 1834
2024
Q4 		$5.25M Buy
+17,000
New +$4.78M 0.01% 1589
2024
Q3 		– Sell
-15,000
Closed -$4.2M – 4466
2024
Q2 		$4.2M Hold
15,000
– – 0.01% 1494
2024
Q1 		$4.01M Buy
+15,000
New +$3.53M 0.01% 1610

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Squarepoint's MDGL Position: Q1 2026 in Review

Squarepoint reduced its Madrigal Pharmaceuticals (MDGL) stake by 29% in Q1 2026, selling an estimated $10.5M and leaving 52,884 shares worth $27.7M. The position accounts for 0.03% of the portfolio, ranked #552.

Squarepoint first reported a position in MDGL in Q4 2015 and has held it in 26 quarters since. The position peaked at $43.6M in Q4 2025. 378 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.

  • Squarepoint held 52,884 shares of Madrigal Pharmaceuticals worth $27.7M as of Q1 2026.
  • Squarepoint sold 22,050 Madrigal Pharmaceuticals shares in Q1 2026, an estimated $10.5M.
  • Madrigal Pharmaceuticals made up 0.03% of Squarepoint's portfolio in Q1 2026, its #552 holding.
  • Squarepoint first reported a position in Madrigal Pharmaceuticals in Q4 2015 and has held it in 26 quarters since.
  • Squarepoint's Madrigal Pharmaceuticals position peaked at $43.6M in Q4 2025.
  • 378 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.